hva

Sultopride hydrochloride (LIN-1418 hydrochloride) is a selective antagonist for dopamine D2 and D3 receptors.

Isohomovanillic acid (Homoisovanillic acid is used as pharmaceutical intermediates.

Mitoquinone mesylate (MitoQ10 mesylate) is a potent TRAP1 inhibitor (IC50=0.2 μM). Mitoquinone mesylate is an antioxidant that prevents oxidative damage and targets mitochondria of TPP.

Sacubitril/Valsartan (LCZ696) is an orally bioavailable, dual angiotensin II receptor and neprilysin inhibitor for the treatment of hypertension and heart failure.

PDP-C1-Ph-Val-Cit is a cleavable ADC linker used in antibody-drug conjugates (ADCs).

H-Val-Ala-OH (Valyl-alanine) is a dipeptide composed of L-Valine and L-Alanine residues, functioning as a metabolite.

L-Valyl-L-phenylalanine has been reported as biocompatible polymer.

Phevamine A (PHVA) is a suppressor of plant immune responses.

H-Val-βNA, also known as L-Valine β-naphthylamide, serves as a substrate for aminopeptidase and Valine arylamidase activities.

H-Val-Obzl.HCl is an amino acid derivative and has a wide range of applications in life science related research.

H-Val-NH2.HCl is an amino acid derivative and has a wide range of applications in life science related research.

H-Val-Tyr-OH (Val-Tyr) is a dipeptide linked by peptide bonds between valine and tyrosine, acting as a potential IKKα inhibitor for cancer and inflammatory disease research.

H-Val-Pro-Pro-OH is an inhibitor of Angiotensin I converting enzyme (ACE)( IC50 : 9 μM).

H-Val-Thr-Cys-Gly-OH is a cell attachment peptide that promotes cell adhesion and facilitates various cell interactions [1].

H-Val-Ala-OH-13C5,15N (Valyl-alanine-13C5,15N) TFA is the 13C- and 15N-labeled version of H-Val-Ala-OH. H-Val-Ala-OH (Valyl-alanine) is a dipeptide composed of residues from L-valine and L-alanine. This compound has metabolic functions and exhibits a bitter taste.

H-Val-Pro-Pro-OH(TFA), a proline peptide derivative from milk, is an ACE inhibitor with IC50 of 9 M.

SP-346 nonapeptide is a pipecolic acid substituted nonapeptide.

MDK-4025 is an inhibitor of the high voltage-activated (HVA) Ca2+ current in pyramidal neurons.

CGP-28014 is an inhibitor of catechol-O-methyltransferase. CGP-28014 increases the renal excretion of both dopamine and dihydroxyphenylacetic acid (DOPAC) but does not affect renal sodium handling indicating a different mechanism of action. CGP-28014 sign